David B. Roberts - 11 Dec 2025 Form 4 Insider Report for LEMAITRE VASCULAR INC (LMAT)

Role: President and Director, Director
Signature: /s/ Laurie A. Churchill, Attorney-in-fact
Issuer symbol: LMAT
Transactions as of: 11 Dec 2025
Transactions value $: -$75,494
Form type: 4
Filing time: 15 Dec 2025, 18:13:27 UTC
Previous filing: 11 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Roberts David B	President and Director, Director	C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON	/s/ Laurie A. Churchill, Attorney-in-fact	15 Dec 2025	0001365731

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LMAT	Common Stock	Options Exercise	$0	+25	+0.11%	$0.00	23.1K	11 Dec 2025	Direct	F1
transaction	LMAT	Common Stock	Tax liability	-$24.8K	-297	-1.28%	$83.36	22.8K	11 Dec 2025	Direct	F2
transaction	LMAT	Common Stock	Options Exercise	$0	+18	+0.08%	$0.00	22.8K	12 Dec 2025	Direct	F1
transaction	LMAT	Common Stock	Tax liability	-$25.4K	-302	-1.32%	$84.00	22.5K	12 Dec 2025	Direct	F3
transaction	LMAT	Common Stock	Options Exercise	$0	+18	+0.08%	$0.00	22.6K	12 Dec 2025	Direct	F1
transaction	LMAT	Common Stock	Tax liability	-$25.4K	-302	-1.34%	$84.00	22.3K	12 Dec 2025	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LMAT	Dividend Equivalent Rights	Options Exercise	$0	-25	-100%	$0.00	0	11 Dec 2025	Common Stock	25		Direct	F5, F6
transaction	LMAT	Dividend Equivalent Rights	Options Exercise	$0	-18	-47.41%	$0.00	20	12 Dec 2025	Common Stock	18		Direct	F7
transaction	LMAT	Dividend Equivalent Rights	Options Exercise	$0	-18	-48.27%	$0.00	19.3	12 Dec 2025	Common Stock	18		Direct	F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
F2	These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/11/2021. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.
F3	These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/12/2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.
F4	These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of performance stock units awarded to the reporting person on 12/12/2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.
F5	These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/11/2021. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F6	Fractional shares released (if any) on each vesting date were settled in cash, resulting in a final balance of zero.
F7	These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F8	These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.